证券代码：688613 证券简称：奥精医疗 公告编号：2025-009 奥精医疗科技股份有限公司 第二届监事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2025 年 4 月 25 日奥精医疗科技股份有限公司（以下简称"公司"或"奥精 医疗"）在公司会议室以现场会议结合通讯方式召开了第二届监事会第十二次会 议。本次会议由监事会主席吴永强主持，应出席监事 3 人，实际出席并表决的监 事 3 人。会议的召开及程序符合《中华人民共和国公司法》（以下简称"《公司 法》"）、《奥精医疗科技股份有限公司公司章程》（以下简称"《公司章程》"） 及《奥精医疗科技股份有限公司监事会议事规则》（以下简称"《监事会议事规 则》"）的相关规定。 二、监事会会议审议情况 (一) 审议通过《关于公司 2024 年度监事会工作报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 2024 年，监事会根据《公司法》、《证券法》、《上海证券交易所科创板 股票上市规则》、《公司章程》及《监事会议 ...

奥精医疗科技股份有限公司监事会 关于2023年限制性股票激励计划首次授予部分 第二个归属期归属名单的核查意见 奥精医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办 法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 和《奥精医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有关规 定，对本次限制性股票激励计划首次授予部分第二个归属期符合归属条件的激励 对象名单进行审核，发表核查意见如下： 经核查，本次激励计划拟归属的 47 名激励对象绩效考核结果合规、真实， 不存在虚假、故意隐瞒等相关情况，符合《公司法》《证券法》等法律、法规和 规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规则》 等法律、法规和规范性文件规定的激励对象条件，符合公司《2023 年限制性股 票激励计划（草案）》规定的激励对象范围，其作为公司本次激励计划激励对象 的主体资格合法、有效，激励对象获授限制性股票的归属条件已成就。 综上所述，监事会 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 500 million for the fiscal year, representing a growth of 25% year-over-year[14]. - In 2024, the company's operating revenue decreased by 9.03% year-on-year to CNY 206,033,014.77, primarily due to the implementation of centralized procurement for orthopedic artificial bone repair materials, which led to a decline in unit ex-factory prices despite increased sales volume[19]. - The net profit attributable to shareholders was -CNY 12,662,162.69, a decrease of 123.35% compared to the previous year, driven by increased costs and market activity expenses following the centralized procurement[21]. - The cash flow from operating activities saw a significant decline of 137.93%, resulting in a net outflow of -CNY 19,603,287.90, attributed to reduced receivables and increased operational costs[21]. - The company's total assets increased by 0.85% year-on-year, reaching CNY 1,539,163,337.61, indicating stability in asset management[20]. - The basic earnings per share for 2024 was -CNY 0.09, a decline of 121.95% compared to CNY 0.41 in 2023, highlighting the impact of reduced profitability[20]. - The weighted average return on equity decreased to -0.91%, down 4.99 percentage points from the previous year, indicating challenges in generating shareholder value[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -CNY 28,371,119.81, a decline of 210.11% year-on-year, reflecting ongoing operational challenges[21]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical solutions, focusing on biocompatible materials[14]. - R&D investment intensity is among the highest in the industry, with breakthroughs including the registration of mineralized collagen/polyester artificial bone repair materials and absorbable collagen hemostatic sponges[30]. - Ongoing R&D projects include collagen dressings and various high-end regenerative medical materials, with clinical trials for mineralized collagen/polyester artificial bone repair materials completed and registration applications submitted[37]. - The company has established a postdoctoral research station, promoting deep integration of industry, academia, and research, enhancing technological innovation and talent cultivation[30]. - The company has increased its R&D investment, focusing on new technology and product development, as well as the transformation of core technological achievements[54]. - The project "Mineralized Collagen/Polyester Artificial Bone Repair Material" has entered the registration phase, leading to a reduction in testing costs compared to the same period last year[62]. - The company has completed biological evaluations and feasibility animal experiments for mineralized collagen artificial bone repair materials targeting the US market, with an investment of CNY 309.42 million, an increase of 246.69% year-on-year[124]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[14]. - The company completed the acquisition of HumanTech Dental in April 2024, entering the dental implant market and establishing a professional marketing team, which is expected to become a new growth driver[32]. - The company is actively pursuing international market expansion, having obtained medical device registration for its artificial bone repair product "BonGold" in Malaysia and progressing with registrations in Vietnam and Indonesia[56]. - The company aims to address the challenges of bone defects through innovative artificial bone repair materials, which are essential for effective treatment[43]. - The company is focusing on expanding its market presence and enhancing its core competitiveness in the regenerative medicine materials sector[132]. - The company plans to accelerate overseas business development, focusing on international markets for dental implant products by 2025[133]. Product Development - New product development includes the launch of a cutting-edge artificial bone technology, expected to enter the market by Q3 2024[14]. - The company’s artificial bone repair products completed clinical trials in Southeast Asia and Latin America, with the BonGold™ product receiving D-class registration in Malaysia, facilitating market expansion[32]. - The company received approval for its collagen hemostatic sponge, expanding its product line in regenerative medical materials and aiming to reduce production costs by using self-produced collagen[36]. - The company has developed a full product line covering orthopedic, neurosurgical, dental, and plastic surgery applications, positioning itself as one of the few providers of comprehensive artificial bone repair materials in China[50]. - The company has established a professional marketing team for dental implants, targeting the mid-to-high-end market and integrating its existing artificial bone repair materials[35]. Governance and Management - The company has established a governance structure with clear responsibilities among the shareholders' meeting, board of directors, supervisory board, and management[136]. - The board of directors has set up specialized committees to provide professional advice for major decisions[136]. - The company has established a remuneration scheme for directors, supervisors, and senior management based on actual business performance and current market levels[149]. - The company has implemented a stock incentive plan, granting 5,016,500 restricted shares to 53 individuals, representing 36.30% of the total[176]. - The company has established a performance evaluation mechanism for senior management, linking compensation to the achievement of operational and profitability targets[184]. Risks and Challenges - The company has no significant risks that could adversely affect its operations, as detailed in the risk management section of the report[14]. - The company faces risks related to product registration renewals, which could adversely affect its operations if policies change[75]. - The company is subject to strict regulatory oversight, and any failure to adapt to changes in regulations could negatively impact its operations[80]. - The company's gross margin is influenced by various factors, including sales prices and production costs, with potential risks of margin decline[78]. - The company has not yet achieved profitability in several of its subsidiaries, which may pose short-term financial risks[78]. Employee and Compensation - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to RMB 12.51 million[149]. - Total remuneration for core technical personnel at the end of the reporting period amounted to RMB 5.10 million[149]. - The company has a structured salary system based on job responsibilities, performance, and market competitiveness to attract and retain talent[163]. - The total number of employees in the parent company is 138, and in major subsidiaries, it is 133, resulting in a total of 271 employees[161]. Environmental and Social Responsibility - The company invested 7.83 million yuan in environmental protection during the reporting period[188]. - The company has established a comprehensive environmental protection system and conducts training on environmental protection[192]. - The company does not fall under the category of key pollutant discharge units and has not faced any administrative penalties for environmental issues during the reporting period[189]. - The company has made donations worth 1.35 million yuan in office furniture and 0.20 million yuan for a public welfare project[199]. - The company actively protects shareholder rights and maintains transparent communication channels with investors[200].

Financial Performance - The company's operating revenue for Q1 2025 was ¥42,459,701.13, a decrease of 10.35% compared to ¥47,360,874.94 in the same period last year[3]. - Net profit attributable to shareholders was ¥1,041,517.76, down 84.99% from ¥6,938,107.45 year-on-year[3]. - Operating profit for Q1 2025 was a loss of ¥192,414.68, compared to a profit of ¥5,810,383.99 in Q1 2024[16]. - Net profit for Q1 2025 was a loss of ¥192,709.03, down from a net profit of ¥5,389,244.56 in Q1 2024[17]. - Basic and diluted earnings per share were both ¥0.01, reflecting an 80% decrease from ¥0.05 in the same period last year[5]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.01, compared to ¥0.05 in Q1 2024[17]. Cash Flow - The net cash flow from operating activities was -¥15,331,420.11, a significant decline of 633.48% compared to -¥2,090,216.95 in the previous year[3]. - Cash flow from operating activities in Q1 2025 was a net outflow of ¥15,331,420.11, compared to a net outflow of ¥2,090,216.95 in Q1 2024[20]. - Cash flow from investing activities in Q1 2025 was a net outflow of ¥3,232,586.82, significantly down from a net inflow of ¥21,233,193.15 in Q1 2024[21]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥136,433,523.59, down from ¥178,413,682.11 at the end of Q1 2024[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,557,562,292.25, an increase of 1.20% from ¥1,539,163,337.61 at the end of the previous year[5]. - The company's current assets totaled RMB 1,221,187,518.20, compared to RMB 1,196,396,879.83 at the end of 2024, reflecting a growth of approximately 2.1%[12]. - The company's inventory increased significantly to RMB 93,901,737.38 from RMB 54,577,004.67, marking a rise of about 71.9%[12]. - Accounts payable rose to RMB 41,165,811.29 from RMB 12,952,487.19, indicating a substantial increase of approximately 217.5%[14]. - The total liabilities of the company were RMB 134,768,205.79, up from RMB 119,200,213.96, representing an increase of about 13.1%[14]. - The company's equity attributable to shareholders reached RMB 1,406,939,573.16, slightly up from RMB 1,402,874,383.57, showing a marginal increase of 0.2%[14]. - The company's long-term borrowings stood at RMB 41,452,173.33, slightly up from RMB 40,752,173.33, indicating a growth of about 1.7%[14]. - The company's total non-current assets were RMB 336,374,774.05, down from RMB 342,766,457.78, reflecting a decrease of approximately 1.9%[13]. Expenses - Research and development expenses totaled ¥5,146,405.26, representing 12.12% of operating revenue, down from 15.95% in the previous year[5]. - Total operating costs increased to ¥46,643,863.61 in Q1 2025, up 1.8% from ¥45,835,228.75 in Q1 2024[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,905[9]. - The top shareholder, HU ERIC GANG, holds 7.00% of the shares, with a total of 9,487,066 shares[9]. Other Income - Non-recurring gains and losses amounted to ¥3,383,047.60, with significant contributions from government subsidies and asset disposals[6]. - Other comprehensive income after tax for Q1 2025 was ¥280,869.33, with no comparable figure reported for Q1 2024[17].

公司 2024 年度利润分配预案综合考虑了公司的经营状况、资金需求及未来 发展等因素， 并参照《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》制定，符合公司和全体股东的利益，独立董事一致同意该利润分配 预案。 奥精医疗科技股份有限公司 第二届董事会独立董事专门会议第二次会议决议 奥精医疗科技股份有限公司（以下简称"公司"）第二届董事会独立董事专 门会议第二次会议于 2025 年 4 月 25 日在公司会议室以现场会议和通讯方式召 开。本次会议由全体独立董事共同推举徐久龙先生担任会议召集人并主持本次会 议，会议应出席独立董事 3 名，实际出席独立董事 3 名。本次会议的召集、召开 和表决程序符合《上市公司独立董事管理办法》等法律、法规、规范性文件和《公 司章程》的有关规定。 本次独立董事专门会议审议情况： （一）审议通过《关于公司<2024 年度内部控制评价报告>的议案》 公司于内部控制评价报告基准日，即 2024 年 12 月 31 日，不存在财务报告 内部控制重大缺陷，亦未发现非财务报告内部控制重大缺陷。 我们认为公司已 按照企业内部控制规范体系和相关规定的要求在所有重大方面保持了有效的 ...

4月24日晚间，奥精医疗科技股份有限公司（以下简称"奥精医疗"或"公司"）发布2024年业绩快报暨业 绩预告更正公告。修正后，公司2024年1-12月实现营业收入2.06亿元，同比下降9.03%，归属于母公司 股东的净利润-1266.22万元，同比下降123.35%；归属于母公司所有者的扣除非经常性损益的净利 润-2837.11万元，同比下降210.11%。 公告称，公司于2025年1月25日和2025年2月28日披露了公司2024年年度业绩预告和2024年度业绩快报， 现对相关内容修正。财务数据未经会计师事务所审计，具体以公司披露的2024年年度报告为准。 公司本次修正后的业绩快报暨业绩预告与公司已披露的《2024年年度业绩预告》和《2024年度业绩快 报》中主要财务数据的差异: (1)更正后的营业总收入为20,603.30万元，比修正前增加27.79万元，增幅0.14%； (2)更正后的营业利润为-736.09万元，比修正前增加701.35万元，增幅为48.79%； (3)更正后的利润总额为-89.64万元，比修正前增加710.34万元，增幅为44.29%； (4)更正后的归属于母公司所有者的净利润为-1 ...

Financial Performance - The corrected total operating revenue is 20,603.30 million CNY, a decrease of 9.03% compared to the same period last year[3] - The corrected operating profit is -736.09 million CNY, reflecting a decrease of 115.02% year-over-year[3] - The corrected net profit attributable to the parent company is -1,266.22 million CNY, a decrease of 123.35% compared to the previous year[3] - The corrected basic earnings per share is -0.09 CNY, representing a decrease of 122.78% year-over-year[4] - The corrected net profit attributable to the parent company after deducting non-recurring gains and losses is -2,837.11 million CNY, a decrease of 210.11% year-over-year[3] - The corrected weighted average return on net assets is -0.91%, a decrease of 122.31% compared to the previous year[4] Assets and Equity - The corrected total assets amount to 154,029.42 million CNY, an increase of 0.92% from the beginning of the reporting period[4] - The corrected net assets attributable to the parent company are 140,287.44 million CNY, reflecting a 1.50% increase from the previous year[4] Adjustments and Cautions - The adjustments were primarily due to changes in the share-based payment amount after determining the number of restricted stock participants[8] - The company emphasizes that the financial data has not yet been audited and investors should be cautious of investment risks[10]

4月21日，奥精医疗今日收盘16.13元，上涨10.03%，最新市净率1.54，创13天以来新低，总市值21.86亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8奥精医疗-120.67-120.671.5421.86亿行业平均 47.6950.834.76102.51亿行业中值29.8830.502.3545.38亿1天益医疗-2712.97-2712.971.7020.18亿2硕世生 物-1868.25-1868.251.1537.40亿3诺唯赞-536.80-536.802.4697.13亿4澳华内镜-516.11258.864.1354.39亿5博 晖创新-360.85-222.173.9855.39亿6康泰医学-265.2731.122.7151.59亿7华大基因-198.26216.862.05201.47亿 9睿昂基因-71.32-71.321.2411.24亿10热景生物-66.94-66.943.68119.99亿11华大智造-52.78-52.783.96316.22 亿 股东方面，截至2024年9月30日，奥精医疗股东户数9779户，较上次减少188户，户均持股市值35. ...

4月10日，奥精医疗今日收盘14.5元，上涨2.11%，最新市净率1.38，总市值19.65亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入1.48亿元，同比-19.22%；净利润488.82万元，同 比-90.95%，销售毛利率74.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)6奥精医疗-108.48-108.481.3819.65亿行业平均 46.1548.384.77102.50亿行业中值29.1329.012.3143.45亿1硕世生物-1773.70-1773.701.1136.64亿2诺唯 赞-508.88-508.882.3392.08亿3博晖创新-340.62-209.723.7552.28亿4康泰医学-270.0231.682.7652.52亿5华 大基因-198.46217.092.05201.67亿7睿昂基因-79.90-79.901.2411.56亿8热景生物-56.75-56.753.12101.72亿9 华大智造-55.34-55.344.15331.55亿10中红医疗-48.80-33.200.7743.45亿11天智航-42.43-42.434. ...